These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25267460)

  • 21. Accuracy of 3 Tesla pelvic phased-array multiparametric MRI in diagnosing prostate cancer at repeat biopsy.
    Pepe P; Garufi A; Priolo G; Dibenedetto G; Salemi M; Pennisi M; Fraggetta F; Aragona F; Barbera M
    Arch Ital Urol Androl; 2014 Dec; 86(4):336-9. PubMed ID: 25641466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Real-time elastography in the diagnosis of prostate cancer: personal experience].
    Romagnoli A; Autieri G; Centrella D; Gastaldi C; Pedaci G; Rivolta L; Pozzi E; Anghileri A; Cerabino M; Bianchi CM; Roggia A
    Urologia; 2010; 77(4):248-53. PubMed ID: 21234867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.
    Baur ADJ; Henkel T; Johannsen M; Speck T; Weißbach L; Hamm B; König F
    Contemp Clin Trials; 2017 May; 56():46-51. PubMed ID: 28279782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.
    van Leeuwen PJ; Hayen A; Thompson JE; Moses D; Shnier R; Böhm M; Abuodha M; Haynes AM; Ting F; Barentsz J; Roobol M; Vass J; Rasiah K; Delprado W; Stricker PD
    BJU Int; 2017 Dec; 120(6):774-781. PubMed ID: 28207981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative biopsy in ambulatory care: performance of MR imaging in a multi-reader environment.
    Scheidler J; Weöres I; Brinkschmidt C; Zeitler H; Panzer S; Scharf M; Heuck A; Siebels M
    Rofo; 2012 Feb; 184(2):130-5. PubMed ID: 22274854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
    Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
    Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
    Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of classical transrectal prostate biopsy versus cognitive registration in rebiopsy.
    Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Cancho Gil MJ; Caño Velasco J; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):228-233. PubMed ID: 30833102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
    Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
    Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    Hambrock T; Somford DM; Hoeks C; Bouwense SA; Huisman H; Yakar D; van Oort IM; Witjes JA; Fütterer JJ; Barentsz JO
    J Urol; 2010 Feb; 183(2):520-7. PubMed ID: 20006859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.
    Hauth E; Hohmuth H; Cozub-Poetica C; Bernand S; Beer M; Jaeger H
    Br J Radiol; 2015 Oct; 88(1054):20150422. PubMed ID: 26268144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
    Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
    Kotb AF; Spaner S; Crump T; Hyndman ME
    World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
    Omri N; Alex S; Jacob B; Ofer N
    Urol Oncol; 2021 Oct; 39(10):728.e7-728.e11. PubMed ID: 33454199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.